Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax: 2014-2025

Historic Long-Term Deferred Tax for Ani Pharmaceuticals (ANIP) over the last 11 years, with Sep 2025 value amounting to $71.4 million.

  • Ani Pharmaceuticals' Long-Term Deferred Tax rose 5.52% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 5.52%. This contributed to the annual value of $85.1 million for FY2024, which is 6.18% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Long-Term Deferred Tax of $71.4 million as of Q3 2025, which was down 22.42% from $92.0 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Long-Term Deferred Tax registered a high of $92.0 million during Q2 2025, and its lowest value of $52.0 million during Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Long-Term Deferred Tax averaged around $83.6 million, with its median value being $85.1 million (2024).
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first soared by 41.40% in 2022, then declined by 19.82% in 2024.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Long-Term Deferred Tax stood at $67.9 million in 2021, then increased by 19.76% to $81.4 million in 2022, then grew by 11.49% to $90.7 million in 2023, then declined by 6.18% to $85.1 million in 2024, then grew by 5.52% to $71.4 million in 2025.
  • Its Long-Term Deferred Tax was $71.4 million in Q3 2025, compared to $92.0 million in Q2 2025 and $88.5 million in Q1 2025.